Document is current
Any future updates will be listed below
-
Authors
Sakanaka, Katsuyuki https://orcid.org/0000-0002-1590-0250
Sasaki, Keita
Tsushima, Takahiro
Machida, Ryunosuke
Hamai, Yoichi
Watanabe, Akinori
Kawabata, Kota
Matsuda, Satoru
Kato, Ken
Fukuda, Haruhiko
Takeuchi, Hiroya
,
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP25ck0106054)
Japan Society for the Promotion of Science (JP24K02401)
- License Information
-
More Information
Article History
Received: 29 September 2025
Accepted: 27 November 2025
First Online: 3 December 2025
Declarations
:
: This study is conducted in accordance with the principles outlined in the Declaration of Helsinki and the Clinical Trials Act in Japan. The JCOG Protocol Review Committee approved this trial protocol (version 1.0) on July 24th, 2024, and centralized approval was obtained from the National Cancer Center Hospital Certified Review Board on September 5th, 2024 (K2024002). Written informed consent will be obtained from all participants.
: Not applicable.
: Katsuyuki Sakanaka has received lecture fees from ONO PHARMACEUTICAL CO., LTD., which are outside the submitted work.Takahiro Tsushima has received lecture fees from Ono Pharmaceutical Co, Ltd; MSD Co, Ltd; Bristol Myers Squibb Co, Ltd. Yoichi Hamai has received lecture fees from Ono Pharmaceutical Co, Ltd; MSD Co, Ltd; Bristol Myers Squibb Co, Ltd. Satoru Matsuda has received lecture fees from Ono Pharmaceutical Co, Ltd; Bristol Myers Squibb Co, Ltd. Ken Kato reports funding to the institution from Merck Sharp & Dohme Corp (MSD), Ono Pharmaceuticals, Bristol Myers Squibb (BMS), Beigene, Shionogi, Merck Biopharma, Oncolys BioPharma, Daiichi Sankyo, Novartis, Taiho Pharmaceutical, Janssen, AstraZeneca, and Chugai. Haruhiko Fukuda has received lecture fees from Chugai Pharmaceutical Co., Ltd.; Kyowa Kirin Co., Ltd. Hiroya Takeuchi has received lecture fees from Ono Pharmaceutical Co, Ltd; MSD Co, Ltd; Bristol Myers Squibb Co, Ltd. Keita Sasaki, Ryunosuke Machida, Akinori Watanabe and Kota Kawabata declare no conflict of interests.
